Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Posterolateral, interbody, and anterior lumbar fusion with instrumentation. Main billing specialties: neurosurgery and orthopedic spine.
Medicare fee-for-service lumbar fusion cases in the 49 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (239 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 199 | 8,753−1%/yr | −1%/yr | 2.50.9× | 2% | 9,020 in 2030+0.5%/yr |
| Texas | 196 | 8,171+0.1%/yr | +0.1%/yr | 3.71.3× | 4% | 9,840 in 2030+3.2%/yr |
| Florida | 165 | 7,337+0.8%/yr | +0.8%/yr | 3.21.1× | 7% | 9,130 in 2030+3.7%/yr |
| Ohio | 90 | 3,677−2.1%/yr | −2.1%/yr | 3.21.1× | 1% | 4,120 in 2030+1.9%/yr |
| Pennsylvania | 89 | 3,644−1.8%/yr | −1.8%/yr | 2.60.9× | 3% | 3,820 in 2030+0.8%/yr |
| New York | 96 | 3,407−0.3%/yr | −0.3%/yr | 1.80.6× | 1% | 4,050 in 2030+2.9%/yr |
| North Carolina | 81 | 3,107−4.5%/yr | −4.5%/yr | 3.01.1× | 0% | 3,140 in 2030+0.2%/yr |
| Georgia | 75 | 3,096−2.3%/yr | −2.3%/yr | 3.41.2× | 3% | 3,640 in 2030+2.7%/yr |
| Illinois | 71 | 3,069−2%/yr | −2%/yr | 2.20.8× | 1% | 3,410 in 2030+1.8%/yr |
| Virginia | 72 | 3,069−1.3%/yr | −1.3%/yr | 2.91.0× | 0% | 3,830 in 2030+3.8%/yr |
| Arizona | 68 | 2,849+1.1%/yr | +1.1%/yr | 3.71.3× | 2% | 3,400 in 2030+3%/yr |
| Tennessee | 71 | 2,726+1.2%/yr | +1.2%/yr | 3.71.3× | 0% | 3,030 in 2030+1.8%/yr |
| Maryland | 58 | 2,364−2.2%/yr | −2.2%/yr | 2.60.9× | 5% | 2,480 in 2030+0.8%/yr |
| Michigan | 60 | 2,354−6.6%/yr | −6.6%/yr | 2.70.9× | 2% | 2,220 in 2030−1%/yr |
| Colorado | 67 | 2,336−3.9%/yr | −3.9%/yr | 4.61.6× | 1% | 2,600 in 2030+1.8%/yr |
| Indiana | 65 | 2,274−3.7%/yr | −3.7%/yr | 3.11.1× | 0% | 2,210 in 2030−0.5%/yr |
| Massachusetts | 61 | 2,186+0.3%/yr | +0.3%/yr | 2.30.8× | 0% | 2,550 in 2030+2.6%/yr |
| South Carolina | 56 | 2,015−1.3%/yr | −1.3%/yr | 2.81.0× | 1% | 2,510 in 2030+3.8%/yr |
| Washington | 49 | 1,995−4.1%/yr | −4.1%/yr | 2.50.9× | 1% | 1,980 in 2030−0.1%/yr |
| Missouri | 51 | 1,950−5.1%/yr | −5.1%/yr | 3.01.1× | 0% | 2,150 in 2030+1.6%/yr |
| Louisiana | 39 | 1,859+1.8%/yr | +1.8%/yr | 4.41.5× | 0% | 2,180 in 2030+2.7%/yr |
| New Jersey | 40 | 1,764+6.8%/yr | +6.8%/yr | 1.60.6× | 11% | 2,120 in 2030+3.1%/yr |
| Oklahoma | 45 | 1,762−4.7%/yr | −4.7%/yr | 3.51.2× | 1% | 1,970 in 2030+1.9%/yr |
| Alabama | 41 | 1,657−1.3%/yr | −1.3%/yr | 3.61.3× | 2% | 1,880 in 2030+2.1%/yr |
| Minnesota | 38 | 1,451−4.5%/yr | −4.5%/yr | 3.11.1× | 2% | 1,850 in 2030+4.1%/yr |
| Kansas | 34 | 1,416−0.7%/yr | −0.7%/yr | 3.41.2× | 6% | 1,630 in 2030+2.3%/yr |
| Kentucky | 33 | 1,251−4%/yr | −4%/yr | 2.60.9× | 1% | 1,500 in 2030+3.1%/yr |
| Utah | 27 | 1,165−2.8%/yr | −2.8%/yr | 5.11.8× | 1% | 1,160 in 2030−0.1%/yr |
| Iowa | 25 | 1,087+7%/yr | +7%/yr | 2.40.8× | 0% | 1,670 in 2030+7.4%/yr |
| Oregon | 23 | 1,070−2.7%/yr | −2.7%/yr | 2.50.9× | 2% | 1,000 in 2030−1.2%/yr |
| Connecticut | 25 | 965+0.5%/yr | +0.5%/yr | 2.81.0× | 0% | 1,000 in 2030+0.5%/yr |
| Nevada | 24 | 953−1.6%/yr | −1.6%/yr | 3.21.1× | 2% | 760 in 2030−3.7%/yr |
| Nebraska | 31 | 952+2%/yr | +2%/yr | 3.61.3× | 3% | 1,140 in 2030+3.1%/yr |
| Wisconsin | 22 | 934−3.1%/yr | −3.1%/yr | 1.60.6× | 5% | 1,390 in 2030+6.8%/yr |
| Idaho | 21 | 882+2.3%/yr | +2.3%/yr | 4.21.5× | 2% | 1,290 in 2030+6.6%/yr |
| Arkansas | 24 | 751−6.1%/yr | −6.1%/yr | 1.90.7× | 5% | 730 in 2030−0.5%/yr |
| Mississippi | 14 | 679−5.9%/yr | −5.9%/yr | 1.80.6× | 0% | 520 in 2030−4.5%/yr |
| Delaware | 12 | 599−2.6%/yr | −2.6%/yr | 3.41.2× | 10% | 670 in 2030+2%/yr |
| South Dakota | 15 | 545−0.8%/yr | −0.8%/yr | 4.11.4× | 0% | 660 in 2030+3.2%/yr |
| Montana | 16 | 506−1.2%/yr | −1.2%/yr | 2.60.9× | 0% | 540 in 2030+1.1%/yr |
| District of Columbia | 8 | 338+2.1%/yr | +2.1%/yr | 5.21.8× | 3% | 370 in 2030+1.6%/yr |
| New Hampshire | 6 | 324−6.1%/yr | −6.1%/yr | 1.40.5× | 0% | 500 in 2030+7.7%/yr |
| West Virginia | 9 | 303−1.5%/yr | −1.5%/yr | 1.40.5× | 0% | 330 in 2030+1.5%/yr |
| Rhode Island | 8 | 294−2.1%/yr | −2.1%/yr | 3.11.1× | 0% | 460 in 2030+7.8%/yr |
| North Dakota | 7 | 286+1%/yr | +1%/yr | 2.81.0× | 0% | 250 in 2030−2.3%/yr |
| New Mexico | 8 | 2820%/yr | 0%/yr | 1.20.4× | 0% | 180 in 2030−7.3%/yr |
| Alaska | 7 | 258+4.9%/yr | +4.9%/yr | 2.10.8× | 0% | 380 in 2030+6.8%/yr |
| Wyoming | 6 | 246−5.5%/yr | −5.5%/yr | 2.20.8× | 8% | 270 in 2030+1.8%/yr |
| Hawaii | 4 | 124−3.3%/yr | −3.3%/yr | 0.90.3× | 36% | 150 in 2030+3%/yr |
Professional codes (what the surgeon bills): CPT 22612, 22630, 22633, 22558; the hospital bills MS-DRG 453, 454, 455, 459, 460, 402, 426, 427, 428, 447, 448, 450, 451, 523, 524, 525.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 1,427 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 325 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Medtronic | 87 |
| Globus Medical | 69 |
| Orthofix | 54 |
| VB Spine | 43 |
| Life Spine | 42 |
| Alphatec | 38 |
| L&K Biomed | 24 |
| Zavation Medical Products | 23 |
| Johnson & Johnson MedTech | 22 |
| Carlsmed | 18 |
| Medacta | 18 |
| Spineology | 18 |
Product codes: KWP (appliance, fixation, spinal interlaminal), KWQ (appliance, fixation, spinal intervertebral body), MAX (intervertebral fusion device with bone graft, lumbar), MBP (filler, bone void, osteoinduction (w/o human growth factor)), MNH (orthosis, spondylolisthesis spinal fixation), MNI (orthosis, spinal pedicle fixation), MPW (filler, recombinant human bone morphogenetic protein, collagen scaffold, osteoinduction), MQP (spinal vertebral body replacement device), MQV (filler, bone void, calcium compound), NKB (thoracolumbosacral pedicle screw system), OVD (intervertebral fusion device with integrated fixation, lumbar), PEK (spinous process plate), PML (bone cement, posterior screw augmentation). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +2 pts since 2019, to 2%.
The 10 busiest do 17% of the cases CMS names in California; 110 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Decompression & minimally invasive spine | 2,544 | 105,318−5.9%/yr | −5.9%/yr | 112,600 in 2030+1.1%/yr |
| Cervical fusion & disc arthroplasty | 962 | 47,639−4%/yr | −4%/yr | 52,600 in 2030+1.7%/yr |
| Kyphoplasty & vertebroplasty | 453 | 42,837−5.7%/yr | −5.7%/yr | 44,800 in 2030+0.7%/yr |
| SI joint fusion | 147 | 7,710+13%/yr | +13%/yr | 14,700 in 2030+11%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 47 companies reported engagement with surgeons in the covered states worth $22M in consulting, speaking, meals and travel tied to these products, about $9,341 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 87 clearances and approvals in the category, 12 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.